nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—Tacrolimus—atopic dermatitis	0.2	0.5	CrCtD
Everolimus—Pimecrolimus—atopic dermatitis	0.2	0.5	CrCtD
Everolimus—MTOR—Pimecrolimus—atopic dermatitis	0.0886	0.326	CbGbCtD
Everolimus—FKBP1A—Pimecrolimus—atopic dermatitis	0.0766	0.282	CbGbCtD
Everolimus—MTOR—Tacrolimus—atopic dermatitis	0.0527	0.194	CbGbCtD
Everolimus—FKBP1A—Tacrolimus—atopic dermatitis	0.0455	0.167	CbGbCtD
Everolimus—Pimecrolimus—Tacrolimus—atopic dermatitis	0.043	0.167	CrCrCtD
Everolimus—Temsirolimus—Pimecrolimus—atopic dermatitis	0.043	0.167	CrCrCtD
Everolimus—Temsirolimus—Tacrolimus—atopic dermatitis	0.043	0.167	CrCrCtD
Everolimus—Sirolimus—Pimecrolimus—atopic dermatitis	0.043	0.167	CrCrCtD
Everolimus—Sirolimus—Tacrolimus—atopic dermatitis	0.043	0.167	CrCrCtD
Everolimus—Tacrolimus—Pimecrolimus—atopic dermatitis	0.043	0.167	CrCrCtD
Everolimus—CYP3A4—Pimecrolimus—atopic dermatitis	0.00217	0.00798	CbGbCtD
Everolimus—CYP3A4—Tacrolimus—atopic dermatitis	0.00129	0.00475	CbGbCtD
Everolimus—CYP3A4—Loratadine—atopic dermatitis	0.000945	0.00347	CbGbCtD
Everolimus—CYP3A4—Methylprednisolone—atopic dermatitis	0.000864	0.00318	CbGbCtD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CABIN1—atopic dermatitis	0.000841	0.057	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—TSLP—atopic dermatitis	0.000658	0.0446	CbGpPWpGaD
Everolimus—CYP3A4—Triamcinolone—atopic dermatitis	0.000655	0.00241	CbGbCtD
Everolimus—CYP3A4—Betamethasone—atopic dermatitis	0.000562	0.00207	CbGbCtD
Everolimus—CYP3A4—Prednisolone—atopic dermatitis	0.000554	0.00204	CbGbCtD
Everolimus—MTOR—IL12-mediated signaling events—IL18R1—atopic dermatitis	0.000542	0.0367	CbGpPWpGaD
Everolimus—CYP3A4—Hydrocortisone—atopic dermatitis	0.000526	0.00193	CbGbCtD
Everolimus—CYP3A4—Prednisone—atopic dermatitis	0.000524	0.00193	CbGbCtD
Everolimus—FKBP1A—Role of Calcineurin-dependent NFAT signaling in lymphocytes—CABIN1—atopic dermatitis	0.000512	0.0347	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—RELB—atopic dermatitis	0.000499	0.0338	CbGpPWpGaD
Everolimus—MTOR—RANKL/RANK Signaling Pathway—RELB—atopic dermatitis	0.00044	0.0298	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—RELB—atopic dermatitis	0.00041	0.0278	CbGpPWpGaD
Everolimus—CYP3A4—Dexamethasone—atopic dermatitis	0.000327	0.0012	CbGbCtD
Everolimus—MTOR—IL4-mediated signaling events—FCER2—atopic dermatitis	0.000326	0.0221	CbGpPWpGaD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL4—atopic dermatitis	0.000306	0.0208	CbGpPWpGaD
Everolimus—MTOR—CXCR3-mediated signaling events—CCL11—atopic dermatitis	0.000289	0.0196	CbGpPWpGaD
Everolimus—MTOR—SREBF and miR33 in cholesterol and lipid homeostasis—PPARA—atopic dermatitis	0.000247	0.0167	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—CCL11—atopic dermatitis	0.000244	0.0165	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—CCL17—atopic dermatitis	0.000242	0.0164	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—STAT6—atopic dermatitis	0.000229	0.0155	CbGpPWpGaD
Everolimus—MTOR—CXCR3-mediated signaling events—CXCR3—atopic dermatitis	0.000206	0.014	CbGpPWpGaD
Everolimus—MTOR—FSH signaling pathway—BDNF—atopic dermatitis	0.000196	0.0133	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—CCL11—atopic dermatitis	0.000195	0.0132	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—STAT6—atopic dermatitis	0.000188	0.0128	CbGpPWpGaD
Everolimus—MTOR—IFN-gamma pathway—CASP1—atopic dermatitis	0.000186	0.0126	CbGpPWpGaD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IFNG—atopic dermatitis	0.000185	0.0126	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—STAT6—atopic dermatitis	0.000184	0.0124	CbGpPWpGaD
Everolimus—MTOR—CXCR3-mediated signaling events—CXCL10—atopic dermatitis	0.000166	0.0113	CbGpPWpGaD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL2—atopic dermatitis	0.000165	0.0112	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FCER1A—atopic dermatitis	0.000141	0.00954	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—IL5—atopic dermatitis	0.000132	0.00894	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MS4A2—atopic dermatitis	0.000131	0.00887	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—CXCL10—atopic dermatitis	0.000119	0.0081	CbGpPWpGaD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—IFNG—atopic dermatitis	0.000113	0.00763	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—BDNF—atopic dermatitis	0.000107	0.00728	CbGpPWpGaD
Everolimus—MTOR—Type II diabetes mellitus—MAPK8—atopic dermatitis	0.000106	0.0072	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—CMA1—atopic dermatitis	0.000101	0.00686	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—KIF3A—atopic dermatitis	0.000101	0.00685	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IL4—atopic dermatitis	9.97e-05	0.00676	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—IL18—atopic dermatitis	9.94e-05	0.00674	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—CD8A—atopic dermatitis	9.79e-05	0.00664	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—IL10—atopic dermatitis	9.64e-05	0.00654	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—IL4—atopic dermatitis	9.63e-05	0.00653	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—IL4—atopic dermatitis	9.38e-05	0.00636	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—NFKBIA—atopic dermatitis	9.23e-05	0.00625	CbGpPWpGaD
Everolimus—FKBP1A—Role of Calcineurin-dependent NFAT signaling in lymphocytes—MAPK8—atopic dermatitis	9.21e-05	0.00624	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—CCR5—atopic dermatitis	8.95e-05	0.00607	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—STAT6—atopic dermatitis	8.56e-05	0.0058	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CTSE—atopic dermatitis	8.5e-05	0.00576	CbGpPWpGaD
Everolimus—MTOR—Type II diabetes mellitus—TNF—atopic dermatitis	8.41e-05	0.0057	CbGpPWpGaD
Everolimus—MTOR—RANKL/RANK Signaling Pathway—NFKBIA—atopic dermatitis	8.14e-05	0.00552	CbGpPWpGaD
Everolimus—MTOR—neck—atopic dermatitis	8.11e-05	0.254	CbGeAlD
Everolimus—MTOR—Cellular responses to stress—CABIN1—atopic dermatitis	8.08e-05	0.00548	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—CARD11—atopic dermatitis	8.08e-05	0.00548	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—STAT6—atopic dermatitis	7.76e-05	0.00526	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—CARD11—atopic dermatitis	7.72e-05	0.00523	CbGpPWpGaD
Everolimus—MTOR—IL2 signaling events mediated by PI3K—IL2—atopic dermatitis	7.61e-05	0.00516	CbGpPWpGaD
Everolimus—MTOR—IFN-gamma pathway—IFNG—atopic dermatitis	7.6e-05	0.00515	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—BDNF—atopic dermatitis	7.3e-05	0.00495	CbGpPWpGaD
Everolimus—FKBP1A—neck—atopic dermatitis	7.3e-05	0.229	CbGeAlD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—atopic dermatitis	7.29e-05	0.00494	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—CARD11—atopic dermatitis	7.14e-05	0.00484	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—NFKBIA—atopic dermatitis	7.12e-05	0.00483	CbGpPWpGaD
Everolimus—MTOR—IFN-gamma pathway—IL1B—atopic dermatitis	6.78e-05	0.00459	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—CXCL8—atopic dermatitis	6.58e-05	0.00446	CbGpPWpGaD
Everolimus—MTOR—ErbB2/ErbB3 signaling events—MAPK8—atopic dermatitis	6.46e-05	0.00438	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—NGF—atopic dermatitis	6.07e-05	0.00411	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IFNG—atopic dermatitis	6.02e-05	0.00408	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—IFNG—atopic dermatitis	5.82e-05	0.00395	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—MAPK8—atopic dermatitis	5.79e-05	0.00392	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—CD4—atopic dermatitis	5.62e-05	0.00381	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—CXCL8—atopic dermatitis	5.6e-05	0.0038	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—FCER1A—atopic dermatitis	5.47e-05	0.00371	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IL1B—atopic dermatitis	5.37e-05	0.00364	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IL2—atopic dermatitis	5.35e-05	0.00363	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	5.34e-05	0.00362	CbGpPWpGaD
Everolimus—MTOR—Wnt Signaling Pathway Netpath—MAPK8—atopic dermatitis	5.34e-05	0.00362	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—IFNG—atopic dermatitis	5.27e-05	0.00357	CbGpPWpGaD
Everolimus—MTOR—skin of body—atopic dermatitis	5.25e-05	0.165	CbGeAlD
Everolimus—MTOR—IL12-mediated signaling events—IL1B—atopic dermatitis	5.19e-05	0.00352	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—MAPK8—atopic dermatitis	5.18e-05	0.00351	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—IL2—atopic dermatitis	5.17e-05	0.00351	CbGpPWpGaD
Everolimus—MTOR—Immune System—CTSE—atopic dermatitis	5.16e-05	0.0035	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—BDNF—atopic dermatitis	5.15e-05	0.00349	CbGpPWpGaD
Everolimus—MTOR—Cardiac Hypertrophic Response—MAPK8—atopic dermatitis	5.1e-05	0.00346	CbGpPWpGaD
Everolimus—MTOR—RANKL/RANK Signaling Pathway—MAPK8—atopic dermatitis	5.1e-05	0.00346	CbGpPWpGaD
Everolimus—MTOR—Costimulation by the CD28 family—CD4—atopic dermatitis	5.09e-05	0.00345	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MS4A2—atopic dermatitis	5.09e-05	0.00345	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	4.82e-05	0.00327	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—CD79A—atopic dermatitis	4.73e-05	0.00321	CbGpPWpGaD
Everolimus—FKBP1A—skin of body—atopic dermatitis	4.72e-05	0.148	CbGeAlD
Everolimus—MTOR—Regulation of Telomerase—IL2—atopic dermatitis	4.68e-05	0.00317	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—NGF—atopic dermatitis	4.57e-05	0.0031	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—DEFB1—atopic dermatitis	4.53e-05	0.00307	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—MAPK8—atopic dermatitis	4.47e-05	0.00303	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—IL1B—atopic dermatitis	4.34e-05	0.00294	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—CD4—atopic dermatitis	4.3e-05	0.00291	CbGpPWpGaD
Everolimus—MTOR—CDC42 signaling events—MAPK8—atopic dermatitis	4.21e-05	0.00285	CbGpPWpGaD
Everolimus—FKBP1A—Disease—GLB1—atopic dermatitis	4.14e-05	0.0028	CbGpPWpGaD
Everolimus—MTOR—Cardiac Hypertrophic Response—TNF—atopic dermatitis	4.04e-05	0.00274	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—MAPK8—atopic dermatitis	3.98e-05	0.0027	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TNF—atopic dermatitis	3.9e-05	0.00264	CbGpPWpGaD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MAPK8—atopic dermatitis	3.78e-05	0.00256	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—NFKBIA—atopic dermatitis	3.77e-05	0.00255	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—atopic dermatitis	3.72e-05	0.00252	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—IL6—atopic dermatitis	3.7e-05	0.00251	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FCER2—atopic dermatitis	3.66e-05	0.00248	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—MAPK8—atopic dermatitis	3.64e-05	0.00247	CbGpPWpGaD
Everolimus—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atopic dermatitis	3.59e-05	0.00243	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KIF3A—atopic dermatitis	3.48e-05	0.00236	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—CXCL8—atopic dermatitis	3.46e-05	0.00234	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NGF—atopic dermatitis	3.43e-05	0.00233	CbGpPWpGaD
Everolimus—MTOR—head—atopic dermatitis	3.43e-05	0.107	CbGeAlD
Everolimus—FKBP1A—Signaling Pathways—CCL22—atopic dermatitis	3.41e-05	0.00231	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	3.35e-05	0.00227	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NFKBIA—atopic dermatitis	3.35e-05	0.00227	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL1B—atopic dermatitis	3.32e-05	0.00225	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—CASP8—atopic dermatitis	3.27e-05	0.00222	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NFKBIA—atopic dermatitis	3.19e-05	0.00217	CbGpPWpGaD
Everolimus—MTOR—Immune System—FCER1A—atopic dermatitis	3.19e-05	0.00216	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IL6—atopic dermatitis	3.15e-05	0.00213	CbGpPWpGaD
Everolimus—FKBP1A—head—atopic dermatitis	3.08e-05	0.0966	CbGeAlD
Everolimus—MTOR—Innate Immune System—STAT6—atopic dermatitis	3.08e-05	0.00209	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—MAPK8—atopic dermatitis	3.04e-05	0.00206	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCL27—atopic dermatitis	3.04e-05	0.00206	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CARD11—atopic dermatitis	3e-05	0.00203	CbGpPWpGaD
Everolimus—MTOR—Immune System—MS4A2—atopic dermatitis	2.96e-05	0.00201	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—NFKBIA—atopic dermatitis	2.96e-05	0.002	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CARD11—atopic dermatitis	2.88e-05	0.00195	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—atopic dermatitis	2.88e-05	0.00195	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SLC11A1—atopic dermatitis	2.77e-05	0.00188	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCL17—atopic dermatitis	2.72e-05	0.00185	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	2.65e-05	0.0018	CbGpPWpGaD
Everolimus—MTOR—Immune System—DEFB1—atopic dermatitis	2.64e-05	0.00179	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—NGF—atopic dermatitis	2.64e-05	0.00179	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KIF3A—atopic dermatitis	2.43e-05	0.00164	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—MAPK8—atopic dermatitis	2.36e-05	0.0016	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CASP1—atopic dermatitis	2.34e-05	0.00158	CbGpPWpGaD
Everolimus—MTOR—Disease—GLB1—atopic dermatitis	2.33e-05	0.00158	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—IL6—atopic dermatitis	2.3e-05	0.00156	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—IL6—atopic dermatitis	2.24e-05	0.00152	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—IL6—atopic dermatitis	2.22e-05	0.0015	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCL11—atopic dermatitis	2.19e-05	0.00149	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CMA1—atopic dermatitis	2.19e-05	0.00149	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—NFKBIA—atopic dermatitis	2.18e-05	0.00148	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—MAPK8—atopic dermatitis	2.17e-05	0.00147	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—IL6—atopic dermatitis	2.16e-05	0.00146	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—IL6—atopic dermatitis	2.16e-05	0.00146	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—MAPK8—atopic dermatitis	2.15e-05	0.00146	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TLR2—atopic dermatitis	2.11e-05	0.00143	CbGpPWpGaD
Everolimus—MTOR—Immune System—KIF3A—atopic dermatitis	2.11e-05	0.00143	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT6—atopic dermatitis	2.06e-05	0.0014	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FCER2—atopic dermatitis	2.06e-05	0.0014	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MAPK8—atopic dermatitis	2e-05	0.00136	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL6—atopic dermatitis	1.94e-05	0.00132	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL22—atopic dermatitis	1.92e-05	0.0013	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—atopic dermatitis	1.91e-05	0.0013	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD79A—atopic dermatitis	1.91e-05	0.00129	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—IL6—atopic dermatitis	1.81e-05	0.00122	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT6—atopic dermatitis	1.79e-05	0.00122	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—IL6—atopic dermatitis	1.79e-05	0.00122	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCR3—atopic dermatitis	1.79e-05	0.00121	CbGpPWpGaD
Everolimus—MTOR—Immune System—CARD11—atopic dermatitis	1.75e-05	0.00118	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL27—atopic dermatitis	1.71e-05	0.00116	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CXCL8—atopic dermatitis	1.65e-05	0.00112	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NPS—atopic dermatitis	1.59e-05	0.00108	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TAC1—atopic dermatitis	1.59e-05	0.00108	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCR3—atopic dermatitis	1.56e-05	0.00106	CbGpPWpGaD
Everolimus—MTOR—Disease—SLC11A1—atopic dermatitis	1.56e-05	0.00106	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD8A—atopic dermatitis	1.54e-05	0.00104	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—IL6—atopic dermatitis	1.53e-05	0.00104	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL17—atopic dermatitis	1.53e-05	0.00104	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL5—atopic dermatitis	1.48e-05	0.001	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—IL6—atopic dermatitis	1.47e-05	0.000995	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—MAPK8—atopic dermatitis	1.46e-05	0.000986	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—IL6—atopic dermatitis	1.45e-05	0.00098	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CCR5—atopic dermatitis	1.4e-05	0.000949	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—IL6—atopic dermatitis	1.38e-05	0.000936	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—IL6—atopic dermatitis	1.37e-05	0.000931	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—IL6—atopic dermatitis	1.37e-05	0.000926	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—MAPK8—atopic dermatitis	1.37e-05	0.000925	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KIF3A—atopic dermatitis	1.36e-05	0.000925	CbGpPWpGaD
Everolimus—MTOR—Immune System—CASP1—atopic dermatitis	1.36e-05	0.000922	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IL6—atopic dermatitis	1.36e-05	0.000922	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL5—atopic dermatitis	1.29e-05	0.000874	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—atopic dermatitis	1.28e-05	0.000867	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6—atopic dermatitis	1.28e-05	0.000867	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—atopic dermatitis	1.28e-05	0.000867	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—IL6—atopic dermatitis	1.27e-05	0.00086	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL10—atopic dermatitis	1.26e-05	0.000857	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—atopic dermatitis	1.26e-05	0.000852	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—atopic dermatitis	1.25e-05	0.000848	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NFKBIA—atopic dermatitis	1.24e-05	0.000841	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL11—atopic dermatitis	1.23e-05	0.000837	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CMA1—atopic dermatitis	1.23e-05	0.000837	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR2—atopic dermatitis	1.23e-05	0.000834	CbGpPWpGaD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—atopic dermatitis	1.2e-05	0.000218	CcSEcCtD
Everolimus—Syncope—Triamcinolone—atopic dermatitis	1.2e-05	0.000218	CcSEcCtD
Everolimus—Syncope—Methylprednisolone—atopic dermatitis	1.19e-05	0.000218	CcSEcCtD
Everolimus—Discomfort—Hydrocortisone—atopic dermatitis	1.19e-05	0.000217	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—NFKBIA—atopic dermatitis	1.19e-05	0.000808	CbGpPWpGaD
Everolimus—Connective tissue disorder—Prednisone—atopic dermatitis	1.19e-05	0.000217	CcSEcCtD
Everolimus—Oedema—Prednisolone—atopic dermatitis	1.18e-05	0.000216	CcSEcCtD
Everolimus—Vomiting—Tacrolimus—atopic dermatitis	1.18e-05	0.000215	CcSEcCtD
Everolimus—Loss of consciousness—Triamcinolone—atopic dermatitis	1.17e-05	0.000214	CcSEcCtD
Everolimus—Loss of consciousness—Methylprednisolone—atopic dermatitis	1.17e-05	0.000213	CcSEcCtD
Everolimus—Rash—Tacrolimus—atopic dermatitis	1.17e-05	0.000213	CcSEcCtD
Everolimus—Dermatitis—Tacrolimus—atopic dermatitis	1.17e-05	0.000213	CcSEcCtD
Everolimus—Shock—Prednisolone—atopic dermatitis	1.17e-05	0.000212	CcSEcCtD
Everolimus—Cough—Triamcinolone—atopic dermatitis	1.16e-05	0.000212	CcSEcCtD
Everolimus—Headache—Tacrolimus—atopic dermatitis	1.16e-05	0.000212	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—STAT6—atopic dermatitis	1.16e-05	0.000787	CbGpPWpGaD
Everolimus—Oedema—Hydrocortisone—atopic dermatitis	1.16e-05	0.000211	CcSEcCtD
Everolimus—Convulsion—Triamcinolone—atopic dermatitis	1.16e-05	0.000211	CcSEcCtD
Everolimus—MTOR—Immune System—CD79A—atopic dermatitis	1.16e-05	0.000784	CbGpPWpGaD
Everolimus—Tachycardia—Prednisolone—atopic dermatitis	1.16e-05	0.000211	CcSEcCtD
Everolimus—Convulsion—Methylprednisolone—atopic dermatitis	1.15e-05	0.00021	CcSEcCtD
Everolimus—Hypertension—Triamcinolone—atopic dermatitis	1.15e-05	0.00021	CcSEcCtD
Everolimus—Hypertension—Methylprednisolone—atopic dermatitis	1.15e-05	0.000209	CcSEcCtD
Everolimus—Infection—Hydrocortisone—atopic dermatitis	1.15e-05	0.000209	CcSEcCtD
Everolimus—Hyperhidrosis—Prednisolone—atopic dermatitis	1.15e-05	0.000209	CcSEcCtD
Everolimus—Shock—Hydrocortisone—atopic dermatitis	1.14e-05	0.000207	CcSEcCtD
Everolimus—Myalgia—Triamcinolone—atopic dermatitis	1.14e-05	0.000207	CcSEcCtD
Everolimus—Nervous system disorder—Hydrocortisone—atopic dermatitis	1.13e-05	0.000207	CcSEcCtD
Everolimus—Arthralgia—Methylprednisolone—atopic dermatitis	1.13e-05	0.000206	CcSEcCtD
Everolimus—Myalgia—Methylprednisolone—atopic dermatitis	1.13e-05	0.000206	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—atopic dermatitis	1.13e-05	0.000768	CbGpPWpGaD
Everolimus—Eye disorder—Prednisone—atopic dermatitis	1.13e-05	0.000206	CcSEcCtD
Everolimus—Anxiety—Methylprednisolone—atopic dermatitis	1.13e-05	0.000206	CcSEcCtD
Everolimus—Tachycardia—Hydrocortisone—atopic dermatitis	1.13e-05	0.000206	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	1.13e-05	0.000205	CcSEcCtD
Everolimus—Flushing—Prednisone—atopic dermatitis	1.12e-05	0.000205	CcSEcCtD
Everolimus—Skin disorder—Hydrocortisone—atopic dermatitis	1.12e-05	0.000205	CcSEcCtD
Everolimus—Ill-defined disorder—Dexamethasone—atopic dermatitis	1.12e-05	0.000205	CcSEcCtD
Everolimus—Ill-defined disorder—Betamethasone—atopic dermatitis	1.12e-05	0.000205	CcSEcCtD
Everolimus—Discomfort—Triamcinolone—atopic dermatitis	1.12e-05	0.000204	CcSEcCtD
Everolimus—Discomfort—Methylprednisolone—atopic dermatitis	1.12e-05	0.000204	CcSEcCtD
Everolimus—MTOR—Innate Immune System—CASP8—atopic dermatitis	1.12e-05	0.000759	CbGpPWpGaD
Everolimus—Hyperhidrosis—Hydrocortisone—atopic dermatitis	1.12e-05	0.000204	CcSEcCtD
Everolimus—Dry mouth—Triamcinolone—atopic dermatitis	1.11e-05	0.000202	CcSEcCtD
Everolimus—Angioedema—Dexamethasone—atopic dermatitis	1.11e-05	0.000202	CcSEcCtD
Everolimus—Angioedema—Betamethasone—atopic dermatitis	1.11e-05	0.000202	CcSEcCtD
Everolimus—Anorexia—Hydrocortisone—atopic dermatitis	1.1e-05	0.000201	CcSEcCtD
Everolimus—Nausea—Tacrolimus—atopic dermatitis	1.1e-05	0.000201	CcSEcCtD
Everolimus—Angiopathy—Prednisone—atopic dermatitis	1.1e-05	0.0002	CcSEcCtD
Everolimus—Immune system disorder—Prednisone—atopic dermatitis	1.09e-05	0.000199	CcSEcCtD
Everolimus—Malaise—Betamethasone—atopic dermatitis	1.09e-05	0.000199	CcSEcCtD
Everolimus—Malaise—Dexamethasone—atopic dermatitis	1.09e-05	0.000199	CcSEcCtD
Everolimus—Oedema—Triamcinolone—atopic dermatitis	1.09e-05	0.000198	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CCL5—atopic dermatitis	1.09e-05	0.000738	CbGpPWpGaD
Everolimus—Syncope—Dexamethasone—atopic dermatitis	1.09e-05	0.000198	CcSEcCtD
Everolimus—Syncope—Betamethasone—atopic dermatitis	1.09e-05	0.000198	CcSEcCtD
Everolimus—Infection—Triamcinolone—atopic dermatitis	1.08e-05	0.000197	CcSEcCtD
Everolimus—Hypotension—Hydrocortisone—atopic dermatitis	1.08e-05	0.000197	CcSEcCtD
Everolimus—Infection—Methylprednisolone—atopic dermatitis	1.08e-05	0.000197	CcSEcCtD
Everolimus—Shock—Triamcinolone—atopic dermatitis	1.07e-05	0.000195	CcSEcCtD
Everolimus—Insomnia—Prednisolone—atopic dermatitis	1.07e-05	0.000195	CcSEcCtD
Everolimus—Alopecia—Prednisone—atopic dermatitis	1.07e-05	0.000195	CcSEcCtD
Everolimus—Shock—Methylprednisolone—atopic dermatitis	1.07e-05	0.000195	CcSEcCtD
Everolimus—Nervous system disorder—Methylprednisolone—atopic dermatitis	1.07e-05	0.000194	CcSEcCtD
Everolimus—Loss of consciousness—Dexamethasone—atopic dermatitis	1.06e-05	0.000194	CcSEcCtD
Everolimus—Loss of consciousness—Betamethasone—atopic dermatitis	1.06e-05	0.000194	CcSEcCtD
Everolimus—Paraesthesia—Prednisolone—atopic dermatitis	1.06e-05	0.000194	CcSEcCtD
Everolimus—Tachycardia—Triamcinolone—atopic dermatitis	1.06e-05	0.000194	CcSEcCtD
Everolimus—Mental disorder—Prednisone—atopic dermatitis	1.06e-05	0.000193	CcSEcCtD
Everolimus—Tachycardia—Methylprednisolone—atopic dermatitis	1.06e-05	0.000193	CcSEcCtD
Everolimus—Skin disorder—Methylprednisolone—atopic dermatitis	1.06e-05	0.000192	CcSEcCtD
Everolimus—Erythema—Prednisone—atopic dermatitis	1.05e-05	0.000192	CcSEcCtD
Everolimus—Malnutrition—Prednisone—atopic dermatitis	1.05e-05	0.000192	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	1.05e-05	0.000192	CcSEcCtD
Everolimus—Hyperhidrosis—Triamcinolone—atopic dermatitis	1.05e-05	0.000192	CcSEcCtD
Everolimus—Hyperhidrosis—Methylprednisolone—atopic dermatitis	1.05e-05	0.000191	CcSEcCtD
Everolimus—Convulsion—Betamethasone—atopic dermatitis	1.05e-05	0.000191	CcSEcCtD
Everolimus—Convulsion—Dexamethasone—atopic dermatitis	1.05e-05	0.000191	CcSEcCtD
Everolimus—Insomnia—Hydrocortisone—atopic dermatitis	1.05e-05	0.000191	CcSEcCtD
Everolimus—Hypertension—Betamethasone—atopic dermatitis	1.05e-05	0.00019	CcSEcCtD
Everolimus—Hypertension—Dexamethasone—atopic dermatitis	1.05e-05	0.00019	CcSEcCtD
Everolimus—Paraesthesia—Hydrocortisone—atopic dermatitis	1.04e-05	0.000189	CcSEcCtD
Everolimus—Myalgia—Dexamethasone—atopic dermatitis	1.03e-05	0.000188	CcSEcCtD
Everolimus—Myalgia—Betamethasone—atopic dermatitis	1.03e-05	0.000188	CcSEcCtD
Everolimus—Anxiety—Dexamethasone—atopic dermatitis	1.03e-05	0.000187	CcSEcCtD
Everolimus—Anxiety—Betamethasone—atopic dermatitis	1.03e-05	0.000187	CcSEcCtD
Everolimus—Discomfort—Dexamethasone—atopic dermatitis	1.02e-05	0.000186	CcSEcCtD
Everolimus—Discomfort—Betamethasone—atopic dermatitis	1.02e-05	0.000186	CcSEcCtD
Everolimus—Dyspepsia—Hydrocortisone—atopic dermatitis	1.02e-05	0.000185	CcSEcCtD
Everolimus—Hypotension—Methylprednisolone—atopic dermatitis	1.02e-05	0.000185	CcSEcCtD
Everolimus—Pain—Prednisolone—atopic dermatitis	1.01e-05	0.000184	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—NGF—atopic dermatitis	1.01e-05	0.000683	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCR3—atopic dermatitis	1.01e-05	0.000682	CbGpPWpGaD
Everolimus—Decreased appetite—Hydrocortisone—atopic dermatitis	1.01e-05	0.000183	CcSEcCtD
Everolimus—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	9.99e-06	0.000182	CcSEcCtD
Everolimus—Fatigue—Hydrocortisone—atopic dermatitis	9.98e-06	0.000182	CcSEcCtD
Everolimus—Vision blurred—Prednisone—atopic dermatitis	9.94e-06	0.000181	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	9.93e-06	0.000181	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	9.9e-06	0.00018	CcSEcCtD
Everolimus—Pain—Hydrocortisone—atopic dermatitis	9.89e-06	0.00018	CcSEcCtD
Everolimus—Oedema—Dexamethasone—atopic dermatitis	9.89e-06	0.00018	CcSEcCtD
Everolimus—Oedema—Betamethasone—atopic dermatitis	9.89e-06	0.00018	CcSEcCtD
Everolimus—Insomnia—Triamcinolone—atopic dermatitis	9.85e-06	0.000179	CcSEcCtD
Everolimus—Insomnia—Methylprednisolone—atopic dermatitis	9.83e-06	0.000179	CcSEcCtD
Everolimus—Infection—Dexamethasone—atopic dermatitis	9.82e-06	0.000179	CcSEcCtD
Everolimus—Infection—Betamethasone—atopic dermatitis	9.82e-06	0.000179	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CCR5—atopic dermatitis	9.8e-06	0.000664	CbGpPWpGaD
Everolimus—Ill-defined disorder—Prednisone—atopic dermatitis	9.79e-06	0.000178	CcSEcCtD
Everolimus—Paraesthesia—Triamcinolone—atopic dermatitis	9.78e-06	0.000178	CcSEcCtD
Everolimus—Feeling abnormal—Prednisolone—atopic dermatitis	9.76e-06	0.000178	CcSEcCtD
Everolimus—Paraesthesia—Methylprednisolone—atopic dermatitis	9.76e-06	0.000178	CcSEcCtD
Everolimus—Anaemia—Prednisone—atopic dermatitis	9.75e-06	0.000178	CcSEcCtD
Everolimus—Shock—Betamethasone—atopic dermatitis	9.73e-06	0.000177	CcSEcCtD
Everolimus—Shock—Dexamethasone—atopic dermatitis	9.73e-06	0.000177	CcSEcCtD
Everolimus—Dyspnoea—Triamcinolone—atopic dermatitis	9.71e-06	0.000177	CcSEcCtD
Everolimus—Nervous system disorder—Betamethasone—atopic dermatitis	9.69e-06	0.000177	CcSEcCtD
Everolimus—Nervous system disorder—Dexamethasone—atopic dermatitis	9.69e-06	0.000177	CcSEcCtD
Everolimus—Agitation—Prednisone—atopic dermatitis	9.69e-06	0.000177	CcSEcCtD
Everolimus—Thrombocytopenia—Betamethasone—atopic dermatitis	9.68e-06	0.000176	CcSEcCtD
Everolimus—Thrombocytopenia—Dexamethasone—atopic dermatitis	9.68e-06	0.000176	CcSEcCtD
Everolimus—Tachycardia—Dexamethasone—atopic dermatitis	9.65e-06	0.000176	CcSEcCtD
Everolimus—Tachycardia—Betamethasone—atopic dermatitis	9.65e-06	0.000176	CcSEcCtD
Everolimus—Angioedema—Prednisone—atopic dermatitis	9.64e-06	0.000176	CcSEcCtD
Everolimus—Dyspepsia—Triamcinolone—atopic dermatitis	9.59e-06	0.000175	CcSEcCtD
Everolimus—Dyspepsia—Methylprednisolone—atopic dermatitis	9.57e-06	0.000174	CcSEcCtD
Everolimus—Hyperhidrosis—Dexamethasone—atopic dermatitis	9.56e-06	0.000174	CcSEcCtD
Everolimus—Hyperhidrosis—Betamethasone—atopic dermatitis	9.56e-06	0.000174	CcSEcCtD
Everolimus—Feeling abnormal—Hydrocortisone—atopic dermatitis	9.54e-06	0.000174	CcSEcCtD
Everolimus—Malaise—Prednisone—atopic dermatitis	9.51e-06	0.000173	CcSEcCtD
Everolimus—MTOR—Immune System—IL18—atopic dermatitis	9.46e-06	0.000642	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	9.46e-06	0.000172	CcSEcCtD
Everolimus—Syncope—Prednisone—atopic dermatitis	9.46e-06	0.000172	CcSEcCtD
Everolimus—Anorexia—Dexamethasone—atopic dermatitis	9.42e-06	0.000172	CcSEcCtD
Everolimus—Anorexia—Betamethasone—atopic dermatitis	9.42e-06	0.000172	CcSEcCtD
Everolimus—Fatigue—Triamcinolone—atopic dermatitis	9.39e-06	0.000171	CcSEcCtD
Everolimus—Fatigue—Methylprednisolone—atopic dermatitis	9.37e-06	0.000171	CcSEcCtD
Everolimus—MTOR—Immune System—CD8A—atopic dermatitis	9.32e-06	0.000632	CbGpPWpGaD
Everolimus—Pain—Triamcinolone—atopic dermatitis	9.32e-06	0.00017	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—IL6—atopic dermatitis	9.29e-06	0.00063	CbGpPWpGaD
Everolimus—Loss of consciousness—Prednisone—atopic dermatitis	9.27e-06	0.000169	CcSEcCtD
Everolimus—Hypotension—Dexamethasone—atopic dermatitis	9.24e-06	0.000168	CcSEcCtD
Everolimus—Hypotension—Betamethasone—atopic dermatitis	9.24e-06	0.000168	CcSEcCtD
Everolimus—MTOR—Innate Immune System—CD4—atopic dermatitis	9.19e-06	0.000623	CbGpPWpGaD
Everolimus—Abdominal pain—Hydrocortisone—atopic dermatitis	9.15e-06	0.000167	CcSEcCtD
Everolimus—Body temperature increased—Hydrocortisone—atopic dermatitis	9.15e-06	0.000167	CcSEcCtD
Everolimus—Convulsion—Prednisone—atopic dermatitis	9.14e-06	0.000166	CcSEcCtD
Everolimus—Hypertension—Prednisone—atopic dermatitis	9.11e-06	0.000166	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	9.01e-06	0.000164	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	9.01e-06	0.000164	CcSEcCtD
Everolimus—Myalgia—Prednisone—atopic dermatitis	8.98e-06	0.000164	CcSEcCtD
Everolimus—Arthralgia—Prednisone—atopic dermatitis	8.98e-06	0.000164	CcSEcCtD
Everolimus—Feeling abnormal—Triamcinolone—atopic dermatitis	8.98e-06	0.000163	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—TAC1—atopic dermatitis	8.97e-06	0.000608	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NPS—atopic dermatitis	8.97e-06	0.000608	CbGpPWpGaD
Everolimus—Feeling abnormal—Methylprednisolone—atopic dermatitis	8.96e-06	0.000163	CcSEcCtD
Everolimus—Anxiety—Prednisone—atopic dermatitis	8.95e-06	0.000163	CcSEcCtD
Everolimus—Insomnia—Dexamethasone—atopic dermatitis	8.94e-06	0.000163	CcSEcCtD
Everolimus—Insomnia—Betamethasone—atopic dermatitis	8.94e-06	0.000163	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	8.92e-06	0.000162	CcSEcCtD
Everolimus—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	8.89e-06	0.000162	CcSEcCtD
Everolimus—Paraesthesia—Dexamethasone—atopic dermatitis	8.88e-06	0.000162	CcSEcCtD
Everolimus—Paraesthesia—Betamethasone—atopic dermatitis	8.88e-06	0.000162	CcSEcCtD
Everolimus—Discomfort—Prednisone—atopic dermatitis	8.87e-06	0.000162	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—CD4—atopic dermatitis	8.83e-06	0.000598	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCR3—atopic dermatitis	8.79e-06	0.000596	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CD4—atopic dermatitis	8.79e-06	0.000596	CbGpPWpGaD
Everolimus—Hypersensitivity—Prednisolone—atopic dermatitis	8.73e-06	0.000159	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—IL6—atopic dermatitis	8.72e-06	0.000591	CbGpPWpGaD
Everolimus—Dyspepsia—Dexamethasone—atopic dermatitis	8.7e-06	0.000158	CcSEcCtD
Everolimus—Dyspepsia—Betamethasone—atopic dermatitis	8.7e-06	0.000158	CcSEcCtD
Everolimus—Body temperature increased—Triamcinolone—atopic dermatitis	8.61e-06	0.000157	CcSEcCtD
Everolimus—Oedema—Prednisone—atopic dermatitis	8.61e-06	0.000157	CcSEcCtD
Everolimus—Abdominal pain—Methylprednisolone—atopic dermatitis	8.59e-06	0.000156	CcSEcCtD
Everolimus—Decreased appetite—Betamethasone—atopic dermatitis	8.59e-06	0.000156	CcSEcCtD
Everolimus—Decreased appetite—Dexamethasone—atopic dermatitis	8.59e-06	0.000156	CcSEcCtD
Everolimus—Infection—Prednisone—atopic dermatitis	8.55e-06	0.000156	CcSEcCtD
Everolimus—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	8.53e-06	0.000155	CcSEcCtD
Everolimus—Gastrointestinal disorder—Betamethasone—atopic dermatitis	8.53e-06	0.000155	CcSEcCtD
Everolimus—Hypersensitivity—Hydrocortisone—atopic dermatitis	8.53e-06	0.000155	CcSEcCtD
Everolimus—Fatigue—Betamethasone—atopic dermatitis	8.52e-06	0.000155	CcSEcCtD
Everolimus—Fatigue—Dexamethasone—atopic dermatitis	8.52e-06	0.000155	CcSEcCtD
Everolimus—Shock—Prednisone—atopic dermatitis	8.47e-06	0.000154	CcSEcCtD
Everolimus—Pain—Dexamethasone—atopic dermatitis	8.45e-06	0.000154	CcSEcCtD
Everolimus—Pain—Betamethasone—atopic dermatitis	8.45e-06	0.000154	CcSEcCtD
Everolimus—Nervous system disorder—Prednisone—atopic dermatitis	8.44e-06	0.000154	CcSEcCtD
Everolimus—Tachycardia—Prednisone—atopic dermatitis	8.4e-06	0.000153	CcSEcCtD
Everolimus—Skin disorder—Prednisone—atopic dermatitis	8.36e-06	0.000152	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—IL5—atopic dermatitis	8.34e-06	0.000565	CbGpPWpGaD
Everolimus—Hyperhidrosis—Prednisone—atopic dermatitis	8.32e-06	0.000152	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—NFKBIA—atopic dermatitis	8.31e-06	0.000563	CbGpPWpGaD
Everolimus—Asthenia—Hydrocortisone—atopic dermatitis	8.3e-06	0.000151	CcSEcCtD
Everolimus—Anorexia—Prednisone—atopic dermatitis	8.21e-06	0.000149	CcSEcCtD
Everolimus—Pruritus—Hydrocortisone—atopic dermatitis	8.19e-06	0.000149	CcSEcCtD
Everolimus—Feeling abnormal—Dexamethasone—atopic dermatitis	8.15e-06	0.000148	CcSEcCtD
Everolimus—Feeling abnormal—Betamethasone—atopic dermatitis	8.15e-06	0.000148	CcSEcCtD
Everolimus—Gastrointestinal pain—Dexamethasone—atopic dermatitis	8.08e-06	0.000147	CcSEcCtD
Everolimus—Gastrointestinal pain—Betamethasone—atopic dermatitis	8.08e-06	0.000147	CcSEcCtD
Everolimus—Hypersensitivity—Triamcinolone—atopic dermatitis	8.03e-06	0.000146	CcSEcCtD
Everolimus—Hypersensitivity—Methylprednisolone—atopic dermatitis	8.01e-06	0.000146	CcSEcCtD
Everolimus—Diarrhoea—Hydrocortisone—atopic dermatitis	7.92e-06	0.000144	CcSEcCtD
Everolimus—MTOR—Disease—CCR5—atopic dermatitis	7.87e-06	0.000534	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Prednisone—atopic dermatitis	7.84e-06	0.000143	CcSEcCtD
Everolimus—Dizziness—Prednisolone—atopic dermatitis	7.83e-06	0.000143	CcSEcCtD
Everolimus—Asthenia—Triamcinolone—atopic dermatitis	7.82e-06	0.000142	CcSEcCtD
Everolimus—Body temperature increased—Dexamethasone—atopic dermatitis	7.81e-06	0.000142	CcSEcCtD
Everolimus—Body temperature increased—Betamethasone—atopic dermatitis	7.81e-06	0.000142	CcSEcCtD
Everolimus—Abdominal pain—Betamethasone—atopic dermatitis	7.81e-06	0.000142	CcSEcCtD
Everolimus—Abdominal pain—Dexamethasone—atopic dermatitis	7.81e-06	0.000142	CcSEcCtD
Everolimus—Asthenia—Methylprednisolone—atopic dermatitis	7.8e-06	0.000142	CcSEcCtD
Everolimus—Insomnia—Prednisone—atopic dermatitis	7.79e-06	0.000142	CcSEcCtD
Everolimus—MTOR—Innate Immune System—MAPK8—atopic dermatitis	7.79e-06	0.000528	CbGpPWpGaD
Everolimus—Paraesthesia—Prednisone—atopic dermatitis	7.73e-06	0.000141	CcSEcCtD
Everolimus—Pruritus—Triamcinolone—atopic dermatitis	7.71e-06	0.00014	CcSEcCtD
Everolimus—Pruritus—Methylprednisolone—atopic dermatitis	7.69e-06	0.00014	CcSEcCtD
Everolimus—Dizziness—Hydrocortisone—atopic dermatitis	7.65e-06	0.000139	CcSEcCtD
Everolimus—Dyspepsia—Prednisone—atopic dermatitis	7.58e-06	0.000138	CcSEcCtD
Everolimus—Decreased appetite—Prednisone—atopic dermatitis	7.48e-06	0.000136	CcSEcCtD
Everolimus—Rash—Prednisolone—atopic dermatitis	7.47e-06	0.000136	CcSEcCtD
Everolimus—Dermatitis—Prednisolone—atopic dermatitis	7.46e-06	0.000136	CcSEcCtD
Everolimus—Diarrhoea—Methylprednisolone—atopic dermatitis	7.44e-06	0.000135	CcSEcCtD
Everolimus—Fatigue—Prednisone—atopic dermatitis	7.42e-06	0.000135	CcSEcCtD
Everolimus—Headache—Prednisolone—atopic dermatitis	7.42e-06	0.000135	CcSEcCtD
Everolimus—Constipation—Prednisone—atopic dermatitis	7.36e-06	0.000134	CcSEcCtD
Everolimus—Vomiting—Hydrocortisone—atopic dermatitis	7.36e-06	0.000134	CcSEcCtD
Everolimus—Rash—Hydrocortisone—atopic dermatitis	7.3e-06	0.000133	CcSEcCtD
Everolimus—Dermatitis—Hydrocortisone—atopic dermatitis	7.29e-06	0.000133	CcSEcCtD
Everolimus—Headache—Hydrocortisone—atopic dermatitis	7.25e-06	0.000132	CcSEcCtD
Everolimus—MTOR—Immune System—NFKBIA—atopic dermatitis	7.23e-06	0.00049	CbGpPWpGaD
Everolimus—Dizziness—Triamcinolone—atopic dermatitis	7.2e-06	0.000131	CcSEcCtD
Everolimus—Dizziness—Methylprednisolone—atopic dermatitis	7.19e-06	0.000131	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CXCL10—atopic dermatitis	7.11e-06	0.000482	CbGpPWpGaD
Everolimus—Feeling abnormal—Prednisone—atopic dermatitis	7.09e-06	0.000129	CcSEcCtD
Everolimus—Asthenia—Dexamethasone—atopic dermatitis	7.09e-06	0.000129	CcSEcCtD
Everolimus—Asthenia—Betamethasone—atopic dermatitis	7.09e-06	0.000129	CcSEcCtD
Everolimus—Gastrointestinal pain—Prednisone—atopic dermatitis	7.04e-06	0.000128	CcSEcCtD
Everolimus—Nausea—Prednisolone—atopic dermatitis	7.04e-06	0.000128	CcSEcCtD
Everolimus—Pruritus—Dexamethasone—atopic dermatitis	6.99e-06	0.000127	CcSEcCtD
Everolimus—Pruritus—Betamethasone—atopic dermatitis	6.99e-06	0.000127	CcSEcCtD
Everolimus—Vomiting—Triamcinolone—atopic dermatitis	6.93e-06	0.000126	CcSEcCtD
Everolimus—Vomiting—Methylprednisolone—atopic dermatitis	6.91e-06	0.000126	CcSEcCtD
Everolimus—Nausea—Hydrocortisone—atopic dermatitis	6.87e-06	0.000125	CcSEcCtD
Everolimus—Rash—Triamcinolone—atopic dermatitis	6.87e-06	0.000125	CcSEcCtD
Everolimus—Dermatitis—Triamcinolone—atopic dermatitis	6.86e-06	0.000125	CcSEcCtD
Everolimus—Rash—Methylprednisolone—atopic dermatitis	6.85e-06	0.000125	CcSEcCtD
Everolimus—Dermatitis—Methylprednisolone—atopic dermatitis	6.85e-06	0.000125	CcSEcCtD
Everolimus—Headache—Triamcinolone—atopic dermatitis	6.83e-06	0.000124	CcSEcCtD
Everolimus—Headache—Methylprednisolone—atopic dermatitis	6.81e-06	0.000124	CcSEcCtD
Everolimus—Body temperature increased—Prednisone—atopic dermatitis	6.81e-06	0.000124	CcSEcCtD
Everolimus—Abdominal pain—Prednisone—atopic dermatitis	6.81e-06	0.000124	CcSEcCtD
Everolimus—Diarrhoea—Betamethasone—atopic dermatitis	6.76e-06	0.000123	CcSEcCtD
Everolimus—Diarrhoea—Dexamethasone—atopic dermatitis	6.76e-06	0.000123	CcSEcCtD
Everolimus—Dizziness—Dexamethasone—atopic dermatitis	6.54e-06	0.000119	CcSEcCtD
Everolimus—Dizziness—Betamethasone—atopic dermatitis	6.54e-06	0.000119	CcSEcCtD
Everolimus—MTOR—Immune System—CASP8—atopic dermatitis	6.52e-06	0.000442	CbGpPWpGaD
Everolimus—Nausea—Triamcinolone—atopic dermatitis	6.47e-06	0.000118	CcSEcCtD
Everolimus—Nausea—Methylprednisolone—atopic dermatitis	6.46e-06	0.000118	CcSEcCtD
Everolimus—Hypersensitivity—Prednisone—atopic dermatitis	6.34e-06	0.000116	CcSEcCtD
Everolimus—Vomiting—Dexamethasone—atopic dermatitis	6.29e-06	0.000114	CcSEcCtD
Everolimus—Vomiting—Betamethasone—atopic dermatitis	6.29e-06	0.000114	CcSEcCtD
Everolimus—Rash—Betamethasone—atopic dermatitis	6.23e-06	0.000114	CcSEcCtD
Everolimus—Rash—Dexamethasone—atopic dermatitis	6.23e-06	0.000114	CcSEcCtD
Everolimus—Dermatitis—Dexamethasone—atopic dermatitis	6.23e-06	0.000113	CcSEcCtD
Everolimus—Dermatitis—Betamethasone—atopic dermatitis	6.23e-06	0.000113	CcSEcCtD
Everolimus—Headache—Betamethasone—atopic dermatitis	6.19e-06	0.000113	CcSEcCtD
Everolimus—Headache—Dexamethasone—atopic dermatitis	6.19e-06	0.000113	CcSEcCtD
Everolimus—Asthenia—Prednisone—atopic dermatitis	6.18e-06	0.000112	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CCL5—atopic dermatitis	6.12e-06	0.000415	CbGpPWpGaD
Everolimus—Pruritus—Prednisone—atopic dermatitis	6.09e-06	0.000111	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CXCL8—atopic dermatitis	5.93e-06	0.000402	CbGpPWpGaD
Everolimus—Diarrhoea—Prednisone—atopic dermatitis	5.89e-06	0.000107	CcSEcCtD
Everolimus—Nausea—Betamethasone—atopic dermatitis	5.87e-06	0.000107	CcSEcCtD
Everolimus—Nausea—Dexamethasone—atopic dermatitis	5.87e-06	0.000107	CcSEcCtD
Everolimus—Dizziness—Prednisone—atopic dermatitis	5.69e-06	0.000104	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—NGF—atopic dermatitis	5.67e-06	0.000384	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—atopic dermatitis	5.66e-06	0.000384	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNG—atopic dermatitis	5.54e-06	0.000376	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCR5—atopic dermatitis	5.51e-06	0.000374	CbGpPWpGaD
Everolimus—Vomiting—Prednisone—atopic dermatitis	5.47e-06	9.97e-05	CcSEcCtD
Everolimus—Rash—Prednisone—atopic dermatitis	5.43e-06	9.88e-05	CcSEcCtD
Everolimus—Dermatitis—Prednisone—atopic dermatitis	5.42e-06	9.88e-05	CcSEcCtD
Everolimus—Headache—Prednisone—atopic dermatitis	5.39e-06	9.82e-05	CcSEcCtD
Everolimus—MTOR—Immune System—CD4—atopic dermatitis	5.35e-06	0.000363	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK8—atopic dermatitis	5.21e-06	0.000353	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GLB1—atopic dermatitis	5.17e-06	0.00035	CbGpPWpGaD
Everolimus—Nausea—Prednisone—atopic dermatitis	5.11e-06	9.31e-05	CcSEcCtD
Everolimus—MTOR—Innate Immune System—IL6—atopic dermatitis	4.97e-06	0.000337	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ADSL—atopic dermatitis	4.95e-06	0.000336	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1B—atopic dermatitis	4.95e-06	0.000335	CbGpPWpGaD
Everolimus—MTOR—Disease—CD4—atopic dermatitis	4.94e-06	0.000335	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—atopic dermatitis	4.93e-06	0.000334	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—atopic dermatitis	4.75e-06	0.000322	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NFKBIA—atopic dermatitis	4.67e-06	0.000317	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK8—atopic dermatitis	4.53e-06	0.000307	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL8—atopic dermatitis	3.33e-06	0.000226	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—atopic dermatitis	3.33e-06	0.000226	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—atopic dermatitis	3.19e-06	0.000216	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK8—atopic dermatitis	2.93e-06	0.000199	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—atopic dermatitis	2.9e-06	0.000196	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—atopic dermatitis	2.67e-06	0.000181	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—atopic dermatitis	1.87e-06	0.000127	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARA—atopic dermatitis	1.68e-06	0.000114	CbGpPWpGaD
